SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Man Kuen Yung, Kwok Wai Lo, Chi Wai Yip, Grace TY Chung, Carol YK Tong, Phyllis FY Cheung, Tan To Cheung, Ronnie TP Poon, Samuel So, Sheung Tat Fan, Siu Tim Cheung, Copy number gain of granulin-epithelin precursor (GEP) at chromosome 17q21 associates with overexpression in human liver cancer, BMC Cancer, 2015, 15, 1

    CrossRef

  2. 2
    Ron C. Gaba, John V. Groth, Ahmad Parvinian, Grace Guzman, Leigh C. Casadaban, Gene Expression in Hepatocellular Carcinoma: Pilot Study of Potential Transarterial Chemoembolization Response Biomarkers, Journal of Vascular and Interventional Radiology, 2015, 26, 5, 723

    CrossRef

  3. 3
    Ravat Panvichian, Anchalee Tantiwetrueangdet, Napat Angkathunyakul, Surasak Leelaudomlipi, TOP2A Amplification and Overexpression in Hepatocellular Carcinoma Tissues, BioMed Research International, 2015, 2015, 1

    CrossRef

  4. 4
    Wilson K.C. Leung, Mian He, Anthony W.H. Chan, Priscilla T.Y. Law, Nathalie Wong, Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion, Cancer Letters, 2015, 362, 1, 97

    CrossRef

  5. 5
    Philip Chong-Hei Kwok, Kwong Chuen Leung, Moon Tong Cheung, Ting Wa Lam, Lok Tin Szeto, Sandas Qi-Hua Chou, Nam Hung Chia, Cheuk Man Tong, Pui Kei Yuen, Chun Hung Cheung, Chun Key Law, Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres, Journal of Gastroenterology and Hepatology, 2014, 29, 11
  6. 6
    Jui Lan, Hsuan-Ying Huang, Sung-Wei Lee, Tzu-Ju Chen, Hui-Chun Tai, Han-Ping Hsu, Kwang-Yu Chang, Chien-Feng Li, TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma, Tumor Biology, 2014, 35, 1, 179

    CrossRef

  7. 7
    Peng Du, Hua Cao, Hao-Rong Wu, Bao-Song Zhu, Hao-Wei Wang, Chun-Wei Gu, Chun-Gen Xing, Wei Chen, Blocking Bcl-2 Leads to Autophagy Activation and Cell Death of the HEPG2 Liver Cancer Cell Line, Asian Pacific Journal of Cancer Prevention, 2013, 14, 10, 5849

    CrossRef

  8. 8
    Liang Song, Tammy Robson, Tamasin Doig, Thomas Brenn, Marie Mathers, Ewan R Brown, Val Doherty, John M S Bartlett, Niall Anderson, David W Melton, DNA repair and replication proteins as prognostic markers in melanoma, Histopathology, 2013, 62, 2
  9. 9
    Lingyan Zhang, Ying Guo, Bibo Li, Juan Qu, Chunbao Zang, Fang Li, Ying Wang, Hua Pang, Shaolin Li, Qingjun Liu, Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods, European Journal of Medical Research, 2013, 18, 1, 35

    CrossRef

  10. 10
    Z G Gulzar, J K McKenney, J D Brooks, Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1, Oncogene, 2013, 32, 1, 70

    CrossRef

  11. 11
    Li Zhou, Ye Jin, Quan-Cai Cui, Ke-Min Jin, Wei-Xun Zhou, Bao-Cai Xing, Low Expression of PAI-2 as a Novel Marker of Portal Vein Tumor Thrombosis and Poor Prognosis in Hepatocellular Carcinoma, World Journal of Surgery, 2013, 37, 3, 608

    CrossRef

  12. 12
    M. Jain, L. Zhang, M. He, Y.-Q. Zhang, M. Shen, E. Kebebew, TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma, Endocrine Related Cancer, 2013, 20, 3, 361

    CrossRef

  13. 13
    Michael Linnebacher, Peter Lorenz, Cornelia Koy, Annika Jahnke, Nadine Born, Felix Steinbeck, Johannes Wollbold, Tobias Latzkow, Hans-Jürgen Thiesen, Michael O. Glocker, Clonality characterization of natural epitope-specific antibodies against the tumor-related antigen topoisomerase IIa by peptide chip and proteome analysis: a pilot study with colorectal carcinoma patient samples, Analytical and Bioanalytical Chemistry, 2012, 403, 1, 227

    CrossRef

  14. 14
    B Taylor-Harding, H Agadjanian, H Nassanian, S Kwon, X Guo, C Miller, B Y Karlan, S Orsulic, C S Walsh, Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment, British Journal of Cancer, 2012, 106, 2, 333

    CrossRef

  15. 15
    Ashish Singhal, Muralidharan Jayaraman, Danny N. Dhanasekaran, Vivek Kohli, Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence, Critical Reviews in Oncology/Hematology, 2012, 82, 2, 116

    CrossRef

  16. 16
    S. W. Birtwell, G. R. Broder, P. L. Roach, H. Morgan, Multiplexed suspension array platform for high-throughput protein assays, Biomedical Microdevices, 2012, 14, 4, 651

    CrossRef

  17. 17
    P. Martinez-Becerra, J. Vaquero, M. R. Romero, E. Lozano, C. Anadon, R. I. R. Macias, M. A. Serrano, N. Grañé-Boladeras, L. Muñoz-Bellvis, L. Alvarez, B. Sangro, M. Pastor-Anglada, J. J. G. Marin, No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors, Molecular Pharmaceutics, 2012, 9, 6, 1693

    CrossRef

  18. 18
    Isabela Werneck da Cunha, Louise De Brot, Kátia Cândido Carvalho, Rafael Malagoli Rocha, José Humberto Fregnani, Roberto Falzoni, Fábio de Oliveira Ferreira, Samuel Aguiar Júnior, Ademar Lopes, Nair Hideko Muto, Luiz F. L. Reis, Fernando Augusto Soares, José Vassallo, Prognostication of Soft Tissue Sarcomas Based on Chromosome 17q Gene and Protein Status: Evaluation of TOP2A, HER-2/neu, and Survivin, Annals of Surgical Oncology, 2012, 19, 6, 1790

    CrossRef

  19. 19
    Atocha Romero, Trinidad Caldés, Eduardo Díaz-Rubio, Miguel Martín, Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?, Clinical and Translational Oncology, 2012, 14, 3, 163

    CrossRef

  20. 20
    W K C Leung, A K K Ching, A W H Chan, T C W Poon, H Mian, A S T Wong, K-F To, N Wong, A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility, Oncogene, 2011, 30, 44, 4464

    CrossRef

  21. 21
    Atocha Romero, Miguel Martín, Maggie C.U. Cheang, José Antonio López García-Asenjo, Belén Oliva, Xiaping He, Miguel de la Hoya, Jose Ángel García Sáenz, Manuel Arroyo Fernández, Eduardo Díaz Rubio, Charles M. Perou, Trinidad Caldés Llopis, Assessment of Topoisomerase II α Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization, The American Journal of Pathology, 2011, 178, 4, 1453

    CrossRef

  22. 22
    Kit-Ying Chung, Ibis K.-C. Cheng, Arthur K.-K. Ching, Jian-Hong Chu, Paul B.-S. Lai, Nathalie Wong, Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition, Hepatology, 2011, 54, 1
  23. 23
    H. Sevim, J. F. Parkinson, K. L. McDonald, Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha?, Journal of Cancer Research and Clinical Oncology, 2011, 137, 11, 1705

    CrossRef

  24. 24
    Mei-Chuan Chen, Chun-Han Chen, Hsiao-Ching Chuang, Samuel K. Kulp, Che-Ming Teng, Ching-Shih Chen, Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells, Hepatology, 2011, 53, 1
  25. 25
    Sebastian Di Cesare, Andre Nantel, Jean-Claude Marshall, Bruno F. Fernandes, Emilia Antecka, Maria E. Orellana, Daniel Abourbih, Antonia M. Saornil, Miguel N. Burnier, Expression profiling of formalin-fixed paraffin embedded primary human uveal melanomas using DASL matrices, Journal of Cancer Research and Clinical Oncology, 2010, 136, 4, 577

    CrossRef

  26. 26
    Yutaka Midorikawa, Yasuyuki Sugiyama, Hiroyuki Aburatani, Molecular targets for liver cancer therapy: From screening of target genes to clinical trials, Hepatology Research, 2010, 40, 1
  27. 27
    Eiman Adel Hasby, Mohammed Alaa Mokhtar, Survivin immunohistochemical expression in hepatocellular carcinoma: Correlation with tumour differentiation and proliferation, Arab Journal of Gastroenterology, 2010, 11, 3, 141

    CrossRef

  28. 28
    Jung-Sun Park, Hye-Sung Kim, Mi-Young Park, Chang-Hyun Kim, Yeun-Jun Chung, Yong-Kil Hong, Tai-Gyu Kim, Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2Kb-restricted T cell epitope, Cancer Immunology, Immunotherapy, 2010, 59, 5, 747

    CrossRef

  29. 29
    Wolfram Goessling, Deciphering Hepatocellular Carcinoma: From Bench to Bedside and Back, Gastroenterology, 2009, 137, 3, 786

    CrossRef

  30. 30
    Sam Birtwell, Hywel Morgan, Microparticle encoding technologies for high-throughput multiplexed suspension assays, Integrative Biology, 2009, 1, 5-6, 345

    CrossRef

  31. 31
    Daniel H. Palmer, Matthew E. Cramp, Systemic Therapy for Hepatocellular Carcinoma: Future Directions,